compound tirzepatide ban update FDA says compounding pharmacies can keep making weight-loss med tirzepatide, for now Compounded Semaglutide & Tirzepatide 2025:

The most common adverse effects were gastrointestinal including nausea, vomiting, and diarrhoea consistent with the GLP-1 receptor agonist drug class

Patients with normal B12 status and no hepatic steatosis typically report zero perceptible effect from MIC injections when diet and activity remain unchanged

Victoza (liraglutide) EPAR Summary of Product Characteristics

A: It is recommended to use the product once a week for maintenance and up to twice a week for faster results

Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al

If injections don't suit you, the newly introduced oral Wegovy pill offers a convenient alternative